MMP13, matrix metallopeptidase 13, 4322

N. diseases: 328; N. variants: 14
Disease: Liver carcinoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.060 Biomarker disease BEFREE Augmented MMP-13 potentiates HCC cell metastasis. 26378022 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.060 AlteredExpression disease BEFREE Moreover, LIFR knockdown could activate phosphoinositide 3-kinase/V-akt Murine Thymoma Viral Oncogene Homolog (PI3K/AKT) signaling through enhancing phosphorylation of Janus kinase 1 (JAK1), which successively promoted matrix metalloproteinase 13 (MMP13) expression and HCC metastasis. 26249360 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.060 Biomarker disease BEFREE Positive correlations between CLU and MMP13, p-Akt, or EIF3I were found in HCC tissues. 25609201 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.060 AlteredExpression disease BEFREE The lower miR-127 expression shows a negative correlation with the higher MMP13 expression in a subset of human HCC specimens. 23762330 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.060 AlteredExpression disease BEFREE Key mechanisms underlying the effect of PPARγ in HCC include upregulation of cell adhesion genes, E-cadherin and SYK (spleen tyrosine kinase), extracellular matrix regulator tissue inhibitors of metalloproteinase (TIMP) 3, tumour suppressor gene retinoblastoma 1, and downregulation of pro-metastatic genes MMP9 (matrix metallopeptidase 9), MMP13, HPSE (heparanase), and Hepatocyte growth factor (HGF). 22472882 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.060 Biomarker disease BEFREE Recently, we firstly examined whether seven functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12, and MMP-13 have any bearing on the risk of hepatocellular carcinoma, but we found none. 18768525 2008